First Wave BioPharma engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Co. is focused on developing its drug product candidate, MS1819, a yeast derived recombinant lipase for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. Co.'s b-lactamase program focuses on products with an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea by resistant bacterial strains induced by parenteral administration of several antibiotic classes. Co.'s compounds in pre-clinical development include: AZX1101 and AZX1103. The FWBI average annual return since 2016 is shown above.
The Average Annual Return on the FWBI average annual return since 2016 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether FWBI average annual return since 2016 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the FWBI average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|